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Brimonidine 0.2% versus Latanoprost 0.005% (Xalatan) to prevent 
intraocular pressure elevation after neodymium:YAG laser posterior 
capsulotomy 
 
Abstract 
Purpose: To compare the efficacy of Brimonidine 0.2% with that of Latanoprost 
0.005% in preventing intraocular pressure (IOP) rise after 
neodymium:YAG(Nd:YAG)laser posterior capsulotomy. 
Setting: Alavi hospital, Ardabil University of medical science, Ardabil, Iran  
Methods: In this double-masked randomized trial, one hundred patients who had 
Nd:YAG laser posterior capsulotomy for posterior capsule opacification were 
prospectively randomized to receive Brimonidine 0.2% (50 patients) or Latanoprost 
0.005% (50 patients) before laser surgery .A masked observer measured IOP by 
Goldmann applanation tonometry before treatment and at 1,2,3,24 hours and 3days 
and 7days after treatment.  
Results: The mean IOP changes from baseline were not statistically different 
between the study groups at 1,2,3,24 hours and 3days and 7days (p=0.058 ,p=0.727 
,p=0.520 ,p=0.187 ,p=0.408 ,p=0.491) after laser surgery. 
The number of eyes with an IOP changes less than baseline, unchanged and with an 
elevation less than 5mmHg, 5mmHg or more ,10mmHg or more at 1hour after surgery 
was statistically different (p=0.038) but at 2,3,24 hours and 3days and 7days were not 
statistically different between the study groups. 
Conclusion: Brimonidine 0.2% and Latanoprost 0.005% given prophylactically 
before Nd:YAG laser capsulotomy were effective in preventing IOP spikes after 
treatment. 
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